Case report
A 48-year-old man with refractory kappa light chain myeThe development of GVHD following allogeneic BMT is known to be closely associated with significant antiloma underwent tandem PBSC transplants in 1996. He had presented in August 1995 (urinary Bence-Jones protein leukaemic activity. Immunological graft-versus-leukaemia (GVL) effects are now well established and are (BJP) excretion 2.4 g/l; plasma cell infiltration, 94%; ␤2-microglobulin, 10.8 mg/l) and failed to respond to three commonly exploited in the treatment of leukaemic relapse following allogeneic transplantation by the use courses of VAD chemotherapy followed by a further three courses of cyclophosphamide-VAMP chemotherapy (BJP of donor lymphocyte infusions. More recently a graftversus-myeloma (GVM) effect following allogeneic excretion, 2.8 g/l; plasma cell infiltration, Ͼ50%). He therefore went on to receive two courses of a cyclosporin Atransplantation has been documented, suggesting that eradication of haematological malignancies following VAD regimen in an attempt to block the presumed MDR phenotype. This treatment led to a partial response (BJP allogeneic transplantation is achieved at least in part by immunological mechanisms. It is now also established excretion, 0.84 g/l; 15% plasma cell infiltration). PBSC mobilisation was then performed using cyclophosphamide that spontaneous GVHD can occur following autologous transplantation and can be induced by cyclosporin A 3 g/m 2 and G-CSF 300 g daily and sufficient CD34-positive cells were collected for a tandem transplant. Some of administration. However, there is only limited evidence that the development of autologous GVHD has an antithe cells collected were stored unmanipulated for use after the first transplant whilst the remainder underwent CD34 ϩ tumour effect. We report for the first time the development of autologous GVHD following PBSC transplanselection using the Ceprate (Cellpro, St Pierre, Belgium) column method for use following the second high-dose protation for myeloma apparently resulting in a GVM effect.
cedure. PCR on the apheresis products revealed contamination with myeloma as demonstrated by PCR for a known Keywords: autologous graft-versus-host disease (GVHD); multiple myeloma; graft-versus-myeloma (GVM) IgH framework III rearrangement even after CD34 ϩ selection. effect; PBSC transplantation He proceeded to the first unselected PBSCT in March 1996, following conditioning with high-dose melphalan Evidence for a graft-versus-myeloma (GVM) effect following allogeneic transplantation has recently been reported. 1, 2 It is known that clinical and histological changes consistent with GVHD can arise in recipients of syngeneic and autologous grafts, but as yet there has been little direct evidence that this can lead to an antitumour effect. We report a patient who spontaneously developed grade II GVHD following a tandem PBSCT which resulted in a significant GVM effect. delayed, only reaching neutrophils Ͼ0.5 ϫ 10 9 /l by day ϩ22 and platelets Ͼ20 ϫ 10 9 /l by day ϩ35. Blood products cells/kg. He was treated with low-dose G-CSF (50 g/m 2 ) from day ϩ1, since this dose has been shown to be sufadministered during and after both transplant procedures were routinely irradiated. Disappointingly no further ficient to enhance haemopoietic recovery post-PBSCT, 3 and reached a neutrophil count of Ͼ0.5 ϫ 10 9 /l by day ϩ13 reduction in kappa BJP excretion was observed in the months following this second transplant (BJP, 0.26 g/l) and and platelets Ͼ20 ϫ 10 9 /l by day ϩ29. The procedure was uncomplicated apart from an episode of suspected PCP the marrow continued to show 10% plasma cell infiltration. Ten weeks following this second transplant he developed pneumonia, and following the transplant his BJP fell from a pretransplant value of 1.8 g/l to 0.28 g/l although he cona widespread pruritic erythematous rash over the trunk and face, clinically suggestive of acute grade II GVHD. A skin tinued to have Ͼ15% plasma cell infiltration in his bone marrow aspirates.
biopsy taken from the forearm confirmed the diagnosis (see Figure 1) . No gastrointestinal symptoms were experienced It was therefore decided to proceed to the second CD34 ϩ selected PBSCT in July 1996 following conditioning with by the patient, his liver function tests (LFTs) remained unchanged and there was no mucosal involvement. Over melphalan 140 mg/m 2 and 12 Gy fractionated TBI. This time he received 1.2 ϫ 10 6 CD34 ϩ selected cells/kg. Again the next few days the skin lesions became more extensive and he was therefore commenced on oral prednisolone he was treated with low-dose G-CSF from day ϩ1 posttransplant, but this time his haemopoietic recovery was (40 mg/day) which led to gradual improvement of the rash, cytogenetic and molecular remission in a patient with CML relapsing after allogeneic transplantation. Like GVHD, GVL also appears to be mediated by donor T lymphocytes and immunotherapy using donor T cells is now common practice following the relapse of CML (and to a lesser extent acute leukaemias) after allogeneic transplantation. Recent reports from at least two groups have suggested a similar antitumour effect following allogeneic transplantation for myeloma, 1,2 their results arguing strongly that immunological graft-versus-myeloma effects are an important contributor to the eradication of disease following such procedures.
The spontaneous development of GVHD following autologous or syngeneic transplantation is now well established, arising in 5-10% of cases and occurring more predictably when cyclosporin A is given post-transplant. [5] [6] [7] It is thought eral studies have reported the successful induction of autologous GVHD using cyclosporin A and/or ␣-interferon.
8,9
However, although in vitro studies have shown that the although attempts to reduce the dose of prednisolone below 10 mg daily have been unsuccessful and he continues to effector cells of autologous GVHD can have a graft-versustumour effect, 10 significant in vivo antitumour activity of have some mild chronic changes. Four weeks following the onset of the rash routine repeat urine examination revealed autologous GVHD has not been convincingly demonstrated. Preliminary studies in Hodgkin's disease and NHL a fall in BJP excretion to 0.08 g/l and subsequent marrow aspiration showed Ͻ2% infiltration with plasma cells. This have suggested a reduced relapse rate compared to historical controls in patients receiving cyclosporin A following low level of BJP excretion was maintained over the next few months suggesting a durable partial remission in his autologous transplantation 11 and an early survival advantage has been reported in breast cancer patients who disease (see Figure 2) . Interestingly molecular studies performed on stored DNA from before and after the tandem developed autologous GVHD as compared to those who did not. 8 Further randomised studies are required to clarify transplant on this patient showed that the onset of autologous GVHD was associated with the development of a clonal this issue. To our knowledge this is the first report of in vivo evi-T cell population as evidenced by clonal TCR␥9 and TCR␥c rearrangements which were not present on pretransdence for a graft-versus-myeloma effect occurring in a patient developing autologous GVHD, although a phase I plant peripheral blood stem cell samples (see Figure 3) . Thus it appears that the development of autologous GVHD trial of cyclosporin A-induced autologous GVHD post-PBSCT in patients with myeloma has been reported. 12 in this patient has led to a significant graft-versus-myeloma effect possibly mediated by the development of a clonal T Recent data suggest that patients with myeloma may develop T cell clones recognising idiotypic immunoglobcell population. We now hope to augment this GVM effect using ␣-interferon.
ulin structures on the surface of myeloma cells as tumourspecific antigens. The development of such clones appears to confer a survival advantage in these patients. 13 It is interesting to note that our patient developed a clonal T cell Discussion population showing TCR␥ rearrangements following the transplant which were not present in the harvested periphGraft-versus-host disease (GVHD) occurring following allogeneic transplantation arises due to the recognition of eral blood stem cells and it is tempting to speculate that this clone may be conferring the graft-versus-myeloma effect foreign host histocompatibility antigens by donor T lymphocytes, with the clinical effects being triggered by the although we have not been able to confirm this. resultant 'cytokine storm'. It is now well established that in myeloid leukaemia the development of GVHD is closely associated with significant antileukaemic effects. Direct References evidence for this graft-versus-leukaemia (GVL) effect was first reported by Kolb et al 4 who showed that infusion of
